Contribution of IL-10 and its -592 A/C polymorphism to cognitive functions in first-episode drug-naive schizophrenia

Brain, Behavior, and Immunity

Volumn 57, Issue , 2016, Pages 116-124

  Xiu, Mei Hong ^a   Tian, Li ^a,b   Chen, Song ^a   Tan, Yun Long ^a   Chen, Da Chun ^a   Chen, Jing ^c   Chen, Nan ^a   De Yang, Fu ^a   Licinio, Julio ^d   Kosten, Thomas R ^e   Soares, Jair C ^f   Zhang, Xiang Yang ^a,f  

^a PEKING UNIVERSITY   (China)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cognition; Cytokines; Genotype; Interleukin 10; Polymorphism; Schizophrenia

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR ALPHA; INTERLEUKIN 10 RECEPTOR BETA; IL10 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; ATTENTION DISTURBANCE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; IL10 GENE; IL10RA GENE; IL10RB GENE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; SCHIZOPHRENIA; SYNAPSE; SYNAPSE VESICLE; BLOOD; BRAIN; COMPLICATION; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PATHOPHYSIOLOGY; YOUNG ADULT;

ADULT; BRAIN; COGNITIVE DYSFUNCTION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN-10; MALE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84960540285     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2016.03.005     Document Type: Article

References (75)

1. Almoguera, B., Riveiro-Alvarez, R., Lopez-Castroman, J., Dorado, P., Lopez-Rodriguez, R., Fernandez-Navarro, P., Baca-Garcia, E., Fernandez-Piqueras, J., Dal-Re, R., Abad-Santos, F., Llerena, A., Ayuso, C., ATA homozigosity in the IL-10 gene promoter is a risk factor for schizophrenia in Spanish females: a case control study. BMC Med. Genet., 12, 2011, 81.
2. Altamura, A.C., Pozzoli, S., Fiorentini, A., Dell'osso, B., Neurodevelopment and inflammatory patterns in schizophrenia in relation to pathophysiology. Prog. Neuropsychopharmacol. Biol. Psychiatry 42 (2013), 63–70.
3. Anderson, G., Berk, M., Dodd, S., Bechter, K., Altamura, A.C., Dell'osso, B., Kanba, S., Monji, A., Fatemi, S.H., Buckley, P., Debnath, M., Das, U.N., Meyer, U., Muller, N., Kanchanatawan, B., Maes, M., Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 42 (2013), 1–4.
4. Arimoto, T., Choi, D.Y., Lu, X., Liu, M., Nguyen, X.V., Zheng, N., Stewart, C.A., Kim, H.C., Bing, G, Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiol. Aging 28:6 (2007), 894–906.
5. Arosio, B., Trabattoni, D., Galimberti, L., Bucciarelli, P., Fasano, F., Calabresi, C., Cazzullo, C.L., Vergani, C., Annoni, G., Clerici, M, Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. Neurobiol. Aging 25:8 (2004), 1009–1015.
6. Bachis, A., Colangelo, A.M., Vicini, S., Doe, P.P., De Bernardi, M.A., Brooker, G., Mocchetti, I, Interleukin-10 prevents glutamate-mediated cerebellar granule cell death by blocking caspase-3-like activity. J. Neurosci. 21:9 (2001), 3104–3112.
7. Bilbo, S.D, Schwarz, J.M., The immune system and developmental programming of brain and behavior. Front. Neuroendocrinol. 33:3 (2012), 267–286.
8. Bocchio Chiavetto, L., Boin, F., Zanardini, R., Popoli, M., Michelato, A., Bignotti, S., Tura, G.B., Gennarelli, M, Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. Biol. Psychiatry 51:6 (2002), 480–484.
9. Borkowska, P., Kucia, K., Rzezniczek, S., Paul-Samojedny, M., Suchanek, R., Owczarek, A., Kowalczyk, M., Fila-Danilow, A., Kowalski, J, Interleukin-1B promoter (-31T/C and -511C/T) polymorphisms in paranoid schizophrenia. Psychiatr. Genet., 22(6), 2012, 311.
10. Boyd, Z.S., Kriatchko, A., Yang, J., Agarwal, N., WaxR, M.B., Patil, V., Interleukin-10 receptor signaling through STAT-3 regulates the apoptosis of retinal ganglion cells in response to stress. Invest. Ophthalmol. Vis. Sci. 44:12 (2003), 5206–5211.
11. Condray, R.J., Yao, K., Cognition, dopamine and bioactive lipids in schizophrenia. Front. Biosci. (Schol. Ed.) 3 (2011), 298–330.
12. Dantzer, R., O'Connor, J.C., Freund, G.G., JohnsonK, R.W., Kelley, W., From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9:1 (2008), 46–56.
13. Di Bona, D., Rizzo, C., Bonaventura, G., Candore, G., Caruso, C., Association between interleukin-10 polymorphisms and Alzheimer's disease: a systematic review and meta-analysis. J. Alzheimers Dis. 29:4 (2012), 751–759.
14. Fatjo-Vilas, M., Pomarol-Clotet, E., Salvador, R., Monte, G.C., Gomar, J.J., Sarro, S., Ortiz-Gil, J., Aguirre, C., Landin-Romero, R., Guerrero-Pedraza, A., Papiol, S., Blanch, J., McKenna, P.J., Fananas, L, Effect of the interleukin-1beta gene on dorsolateral prefrontal cortex function in schizophrenia: a genetic neuroimaging study. Biol. Psychiatry 72:9 (2012), 758–765.
15. Fernandez-Chacon, R., Konigstorfer, A., Gerber, S.H., Garcia, J., Matos, M.F., Stevens, C.F., Brose, N., Rizo, J., RosenmundT, C., Sudhof, C., Synaptotagmin I functions as a calcium regulator of release probability. Nature 410:6824 (2001), 41–49.
16. Fineberg, A.M.L., Ellman, M., Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol. Psychiatry 73:10 (2013), 951–966.
17. Frydecka, D., Misiak, B., Beszlej, J.A., Karabon, L., Pawlak-Adamska, E., Tomkiewicz, A., Partyka, A., Jonkisz, A., Kiejna, A., Genetic variants in transforming growth factor-beta gene (TGFB1) affect susceptibility to schizophrenia. Mol. Biol. Rep. 40:10 (2013), 5607–5614.
18. Girgis, R.R., KumarA, S.S., Brown, S., The cytokine model of schizophrenia: emerging therapeutic strategies. Biol. Psychiatry 75:4 (2014), 292–299.
19. Gresa-Arribas, N., Vieitez, C., Dentesano, G., Serratosa, J., Saura, J., Sola, C., Modelling neuroinflammation in vitro: a tool to test the potential neuroprotective effect of anti-inflammatory agents. PLoS One, 7(9), 2012, e45227.
20. Huang da, W., Sherman, B.T., Zheng, X., Yang, J., Imamichi, T., Stephens, R., Lempicki, A., Extracting biological meaning from large gene lists with DAVID. Curr. Protoc. Bioinf., 2009 Chapter 13, Unit 13 11.
21. Hwang, Y., Kim, J., Shin, J.Y., Kim, J.I., Seo, J.S., Webster, M.J., Lee, D., Kim, S., Gene expression profiling by mRNA sequencing reveals increased expression of immune/inflammation-related genes in the hippocampus of individuals with schizophrenia. Transl. Psychiatry, 3, 2013, e321.
22. Ibrahim, H.M.C., Tamminga, A., Schizophrenia: treatment targets beyond monoamine systems. Annu. Rev. Pharmacol. Toxicol. 51 (2011), 189–209.
23. Ibrahim, H.M.C., Tamminga, A., Treating impaired cognition in schizophrenia. Curr. Pharm. Biotechnol. 13:8 (2012), 1587–1594.
24. Jun, T.Y., Pae, C.U., Kim, K.S., Han, H., Serretti, A, Interleukin-10 gene promoter polymorphism is not associated with schizophrenia in the Korean population. Psychiatry Clin. Neurosci. 57:2 (2003), 153–159.
25. Kahn, R.S., Keefe, R.S., Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry 70:10 (2013), 1107–1112.
26. Kaminska, T., Wysocka, A., Marmurowska-Michalowska, H., Dubas-Slemp, H., Kandefer-Szerszen, M., Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch. Immunol. Ther. Exp. (Warsz) 49:6 (2001), 439–445.
27. Kelly, A., Lynch, A., Vereker, E., Nolan, Y., Queenan, P., Whittaker, E., O'NeillM, L.A., Lynch, A., The anti-inflammatory cytokine, interleukin (IL)-10, blocks the inhibitory effect of IL-1 beta on long term potentiation. A role for JNK. J. Biol. Chem. 276:49 (2001), 45564–45572.
28. Khandaker, G., Dantzer, M.R., Is there a role for immune-to-brain communication in schizophrenia?. Psychopharmacology, 2015.
29. Kiyota, T., Ingraham, K.L., Swan, R.J., Jacobsen, M.T., Andrews, S.J., Ikezu, T, AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice. Gene Ther. 19:7 (2012), 724–733.
30. Krabbe, K.S., Mortensen, E.L., Avlund, K., Pilegaard, H., Christiansen, L., Pedersen, A.N., Schroll, M., Jorgensen, T., Pedersen, B.K., Bruunsgaard, H., Genetic priming of a proinflammatory profile predicts low IQ in octogenarians. Neurobiol. Aging 30:5 (2009), 769–781.
31. Kubistova, A., Horacek, J., Novak, T., Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls. Psychiatr. Danub. 24:Suppl. 1 (2012), S153–S156.
32. Kunz, M., Cereser, K.M., Goi, P.D., Fries, G.R., Teixeira, A.L., Fernandes, B.S., Belmonte-de-Abreu, P.S., Kauer-Sant'Anna, M., KapczinskiC, F., Gama, S., Serum levels of IL-6, IL-10 and TNF-alpha in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev. Bras. Psiquiatr. 33:3 (2011), 268–274.
33. Lio, D., Licastro, F., Scola, L., Chiappelli, M., Grimaldi, L.M., Crivello, A., Colonna-Romano, G., Candore, G., Franceschi, C., Caruso, C., Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease. Genes Immun. 4:3 (2003), 234–238.
34. Lung, F.W., YangB, M.C., Shu, C., The interleukin 10 promoter haplotype ACA and the long-form variant of the DRD4 uVNTR polymorphism are associated with vulnerability to schizophrenia. Psychiatry Res. 188:2 (2011), 294–296.
35. Lynch, A.M., Walsh, C., Delaney, A., Nolan, Y., CampbellM, V.A., Lynch, A., Lipopolysaccharide-induced increase in signalling in hippocampus is abrogated by IL-10–a role for IL-1 beta?. J. Neurochem. 88:3 (2004), 635–646.
36. Ma, S.L., Tang, N.L., LamH, L.C., Chiu, F., The association between promoter polymorphism of the interleukin-10 gene and Alzheimer's disease. Neurobiol. Aging 26:7 (2005), 1005–1010.
37. Maes, M., Bocchio Chiavetto, L., Bignotti, S., Battisa Tura, G.J., Pioli, R., Boin, F., Kenis, G., Bosmans, E., de JonghC, R., Altamura, A., Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr. Res. 54:3 (2002), 281–291.
38. McAfoose, J.B., Baune, T., Evidence for a cytokine model of cognitive function. Neurosci. Biobehav. Rev. 33:3 (2009), 355–366.
39. Meyer, U., Murray, P.J., Urwyler, A., Yee, B.K., Schedlowski, M., Feldon, J., Adult behavioral and pharmacological dysfunctions following disruption of the fetal brain balance between pro-inflammatory and IL-10-mediated anti-inflammatory signaling. Mol Psychiatry 13:2 (2008), 208–221.
40. Miller, A.H., MaleticC, V., Raison, L., Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65:9 (2009), 732–741.
41. Miller, B.J., Buckley, P., Seabolt, W., Mellor, A., Kirkpatrick, B., Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 70:7 (2011), 663–671.
42. Molina-Holgado, E., Vela, J.M., Arevalo-Martin, A., Guaza, C., LPS/IFN-gamma cytotoxicity in oligodendroglial cells: role of nitric oxide and protection by the anti-inflammatory cytokine IL-10. Eur. J. Neurosci. 13:3 (2001), 493–502.
43. Molina-Holgado, E., Arevalo-Martin, A., Ortiz, S., Vela, J.M., Guaza, C., Theiler's virus infection induces the expression of cyclooxygenase-2 in murine astrocytes: inhibition by the anti-inflammatory cytokines interleukin-4 and interleukin-10. Neurosci. Lett. 324:3 (2002), 237–241.
44. Muller, N., The role of anti-inflammatory treatment in psychiatric disorders. Psychiatr. Danub. 25:3 (2013), 292–298.
45. Muller, N., Myint, A.M., Schwarz, M.J., Inflammation in schizophrenia. Adv. Protein Chem. Struct. Biol. 88 (2012), 49–68.
46. Muller, N., Weidinger, E., Leitner, B., Schwarz, M.J., The role of inflammation in schizophrenia. Front. Neurosci., 9, 2015, 372.
47. O'Brien, S.M., ScullyT, P., Dinan, G., Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Res. 160:3 (2008), 256–262.
48. Ooboshi, H., Ibayashi, S., Shichita, T., Kumai, Y., Takada, J., Ago, T., Arakawa, S., Sugimori, H., Kamouchi, M., Kitazono, T., Iida, M., Postischemic gene transfer of interleukin-10 protects against both focal and global brain ischemia. Circulation 111:7 (2005), 913–919.
49. Ozbey, U., Tug, E., Namli, M., Interleukin-10 gene promoter polymorphism in patients with schizophrenia in a region of East Turkey. World J Biol Psychiatry 10:4 Pt 2 (2009), 461–468.
50. Paul-Samojedny, M., Kowalczyk, M., Suchanek, R., Owczarek, A., Fila-Danilow, A., Szczygiel, A., Kowalski, J., Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia–a case-control study. J. Mol. Neurosci. 42:1 (2010), 112–119.
51. Paul-Samojedny, M., Owczarek, A., Kowalczyk, M., Suchanek, R., Palacz, M., Kucia, K., Fila-Danilow, A., Borkowska, P., Kowalski, J., Association of interleukin 2 (IL-2), interleukin 6 (IL-6), and TNF-alpha (TNFalpha) gene polymorphisms with paranoid schizophrenia in a Polish population. J. Neuropsychiatry Clin. Neurosci. 25:1 (2013), 72–82.
52. Pedrini, M., Massuda, R., Fries, G.R., de Bittencourt Pasquali, M.A., Schnorr, C.E., Moreira, J.C., Teixeira, A.L., Lobato, M.I., Walz, J.C., Belmonte-de-Abreu, P.S., Kauer-Sant'Anna, M., KapczinskiC, F., Gama, S., Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J. Psychiatr. Res. 46:6 (2012), 819–824.
53. Piraino, B., Vollmer-ConnaA, U., Lloyd, R., Genetic associations of fatigue and other symptom domains of the acute sickness response to infection. Brain Behav. Immun. 26:4 (2012), 552–558.
54. Potvin, S., Stip, E., Sepehry, A.A., Gendron, A., Bah, R., Kouassi, E., Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 63:8 (2008), 801–808.
55. Qian, L., HongP, J.S., Flood, M., Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: neuroprotective effect of interleukin 10. J. Neural Transm. Suppl. 70 (2006), 367–371.
56. Rady, P.L., Matalon, R., Grady, J., Smith, E.M., Hudnall, S.D., Kellner, L.H., Nitowsky, H., TyringT, S.K., Hughes, K., Comprehensive analysis of genetic polymorphisms in the interleukin-10 promoter: implications for immune regulation in specific ethnic populations. Genet Test 8:2 (2004), 194–203.
57. Randolph, C., Tierney, M.C., MohrT, E., Chase, N., The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J. Clin. Exp. Neuropsychol. 20:3 (1998), 310–319.
58. Remarque, E.J., Bollen, E.L., Weverling-Rijnsburger, A.W., Laterveer, J.C., BlauwR, G.J., Westendorp, G., Patients with Alzheimer's disease display a pro-inflammatory phenotype. Exp. Gerontol. 36:1 (2001), 171–176.
59. Sharma, S., Yang, B., Xi, X., Grotta, J.C., AronowskiS, J., Savitz, I., IL-10 directly protects cortical neurons by activating PI-3 kinase and STAT-3 pathways. Brain Res. 1373 (2011), 189–194.
60. Sperner-Unterweger, B., Fuchs, D., Schizophrenia and psychoneuroimmunology: an integrative view. Curr. Opin. Psychiatry 28:3 (2015), 201–206.
61. Stefansson, H., Ophoff, R.A., Steinberg, S., Andreassen, O.A., Cichon, S., Rujescu, D., Werge, T., Pietilainen, O.P., Mors, O., Mortensen, P.B., Sigurdsson, E., Gustafsson, O., Nyegaard, M., Tuulio-Henriksson, A., Ingason, A., Hansen, T., Suvisaari, J., Lonnqvist, J., Paunio, T., Borglum, A.D., Hartmann, A., Fink-Jensen, A., Nordentoft, M., Hougaard, D., Norgaard-Pedersen, B., Bottcher, Y., Olesen, J., Breuer, R., Moller, H.J., Giegling, I., Rasmussen, H.B., Timm, S., Mattheisen, M., Bitter, I., Rethelyi, J.M., Magnusdottir, B.B., Sigmundsson, T., Olason, P., Masson, G., Gulcher, J.R., Haraldsson, M., Fossdal, R., Thorgeirsson, T.E., Thorsteinsdottir, U., Ruggeri, M., Tosato, S., Franke, B., Strengman, E., Kiemeney, L.A., Melle, I., Djurovic, S., Abramova, L., Kaleda, V., Sanjuan, J., de Frutos, R., Bramon, E., Vassos, E., Fraser, G., Ettinger, U., Picchioni, M., Walker, N., Toulopoulou, T., Need, A.C., Ge, D., Yoon, J.L., Shianna, K.V., Freimer, N.B., Cantor, R.M., Murray, R., Kong, A., Golimbet, V., Carracedo, A., Arango, C., Costas, J., Jonsson, E.G., Terenius, L., Agartz, I., Petursson, H., Nothen, M.M., Rietschel, M., Matthews, P.M., Muglia, P., Peltonen, L., St Clair, D., Goldstein, D.B., StefanssonD, K., Collier, A., Common variants conferring risk of schizophrenia. Nature 460:7256 (2009), 744–747.
62. Steinke, J.W., Barekzi, E., Hagman, J., Borish, L., Functional analysis of -571 IL-10 promoter polymorphism reveals a repressor element controlled by sp1. J Immunol 173:5 (2004), 3215–3222.
63. Strle, K., Zhou, J.H., Shen, W.H., Broussard, S.R., Johnson, R.W., Freund, G.G., DantzerK, R., Kelley, W., Interleukin-10 in the brain. Crit. Rev. Immunol. 21:5 (2001), 427–449.
64. Sun, H., Wang, F., Fan, H., Yan, Q., Cui, K., Yuan, W., Zhao, F., Zhao, L., Yuan, J., Yang, F., KostenX, T.R., Zhang, Y., The interaction of polymorphisms of IL10 and DBH was associated with general symptoms of PANSS with TD in Chinese Han schizophrenic patients. PLoS ONE, 8(8), 2013, e70963.
65. Torkildsen, O., Utsi, E., Harbo, H.F., Mellgren, S.I., VedelerK, C.A., Myhr, M., Ethnic variations of IL-10 polymorphisms in a Sami and Norwegian population. Scand. J. Immunol. 62:1 (2005), 71–74.
66. Turner, D.M., Williams, D.M., Sankaran, D., Lazarus, M., SinnottI, P.J., Hutchinson, V., An investigation of polymorphism in the interleukin-10 gene promoter. Eur. J. Immunogenet. 24:1 (1997), 1–8.
67. Westendorp, R.G., Langermans, J.A., Huizinga, T.W., Elouali, A.H., Verweij, C.L., BoomsmaJ, D.I., Vandenbroucke, P., Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349:9046 (1997), 170–173.
68. Wilson, C.J., FinchH, C.E., Cohen, J., Cytokines and cognition–the case for a head-to-toe inflammatory paradigm. J. Am. Geriatr. Soc. 50:12 (2002), 2041–2056.
69. Woodcock, T., Morganti-Kossmann, M.C., The role of markers of inflammation in traumatic brain injury. Front. Neurol., 4, 2013, 18.
70. Xiu, M.H., Yang, G.G., Tan, Y.L., Chen da, C., Tan, S.P., Wang, Z.R., Yang, F.D., Okusaga, O., Soares, J.C., Zhang, X.Y., Decreased interleukin-10 serum levels in first-episode drug-naive schizophrenia: relationship to psychopathology. Schizophr. Res. 156:1 (2014), 9–14.
71. Yirmiya, R.I.Goshen., Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav. Immun. 25:2 (2011), 181–213.
72. Yu, L., Yang, M.S., Zhao, J., Shi, Y.Y., Zhao, X.Z., Yang, J.D., Liu, Z.J., Gu, N.F., Feng, G.Y., He, L., An association between polymorphisms of the interleukin-10 gene promoter and schizophrenia in the Chinese population. Schizophr. Res. 71:1 (2004), 179–183.
73. Zhang, B.H., ZhangZ, W.F., Wang, R., Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) as a screening test in Chinese: reliability and validity. Chin. Ment. Health J. 28 (2009), 865–869.
74. Zhang, X.Y., Tang, W., Xiu, M.H., Chen da, C., Yang, F.D, Tan, Y.L., Wang, Z.R., Zhang, F., Liu, J., Liu, L., Chen, Y., Wen, N., Kosten, T.R., Interleukin 18 and cognitive impairment in first episode and drug naive schizophrenia versus healthy controls. Brain Behav. Immun. 32 (2013), 105–111.
75. Zhou, Z., Peng, X., Insolera, R., Fink, D.J., Mata, M., IL-10 promotes neuronal survival following spinal cord injury. Exp. Neurol. 220:1 (2009), 183–190.